Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Mutations in the alternative complement pathway in multiple myeloma patients with carfilzomib-induced thrombotic microangiopathy
Maria Moscvin, Christine‐Ivy Liacos, Tianzeng Chen, et al.
Blood Cancer Journal (2023) Vol. 13, Iss. 1
Open Access | Times Cited: 17

Showing 17 citing articles:

Clinical features, treatment, and outcomes of patients with carfilzomib induced thrombotic microangiopathy
Weilun Fang, Wei Sun, Weijin Fang, et al.
International Immunopharmacology (2024) Vol. 134, pp. 112178-112178
Closed Access | Times Cited: 11
New Biological Therapies for Multiple Myeloma
Alfred L. Garfall
Annual Review of Medicine (2023) Vol. 75, Iss. 1, pp. 13-29
Closed Access | Times Cited: 14
Abnormalities of primary and secondary hemostasis in multiple myeloma: insights from studies on thrombopoiesis, the coagulation system, and the bone marrow microenvironment
Jahangir Abdi, Payman Nasr
Frontiers in Hematology (2025) Vol. 4
Open Access
Carfilzomib-induced thrombotic microangiopathy (TMA): an under-recognised spectrum of disease from microangiopathic haemolysis to subclinical TMA
Royston Ponraj, Adam Bryant, Lindsay Dunlop, et al.
Blood Cancer Journal (2023) Vol. 13, Iss. 1
Open Access | Times Cited: 7
Carfilzomib-associated thrombotic microangiopathy: clinical features and outcomes
Adrien Joseph, Stéphanie Harel, Laurent Mesnard, et al.
Nephrology Dialysis Transplantation (2024) Vol. 39, Iss. 12, pp. 2067-2078
Closed Access | Times Cited: 2
Carfilzomib-induced thrombotic microangiopathy (TMA) refractory to eculizumab: A case report and literature review
Mina Meseha, Dan Qu, Jill Lykon, et al.
Annals of Hematology (2024) Vol. 103, Iss. 10, pp. 4313-4317
Open Access | Times Cited: 2
Genetic and Functional Evidence of Complement Dysregulation in Multiple Myeloma Patients with Carfilzomib-Induced Thrombotic Microangiopathy Compared to Controls
Eleni Gavriilaki, Dimitra Dalampira, Foteini Theodorakakou, et al.
Journal of Clinical Medicine (2022) Vol. 11, Iss. 12, pp. 3355-3355
Open Access | Times Cited: 11
Carfilzomib-Induced Thrombotic Microangiopathy: Focus on Pathogenesis
Odianosen Eigbire‐Molen, Daniela Hermelin, Douglas P. Blackall
Journal of Medical Cases (2022) Vol. 13, Iss. 6, pp. 274-280
Open Access | Times Cited: 8
Thrombotic microangiopathy associated with anticancer and immune system targeting drugs: New insights from real‐world data using the WHO pharmacovigilance database
Guillaume Bayer, Florent von Tokarski, Benjamin Thoreau, et al.
Journal of Internal Medicine (2023) Vol. 294, Iss. 5, pp. 665-678
Closed Access | Times Cited: 4
Pharmacotherapy considerations in patients who develop acute kidney injury during anti-cancer therapy
E Parodi, Maura Rossi, Achille Bottiglieri, et al.
Expert Opinion on Pharmacotherapy (2024) Vol. 25, Iss. 5, pp. 595-610
Closed Access | Times Cited: 1
Endothelial injury and dysfunction with emerging immunotherapies in multiple myeloma, the impact of COVID-19, and endothelial protection with a focus on the evolving role of defibrotide
Clifton C. Mo, Edward Richardson, Eleonora Calabretta, et al.
Blood Reviews (2024) Vol. 66, pp. 101218-101218
Open Access | Times Cited: 1
Complement C3d enables protective immunity capable of distinguishing spontaneously transformed from non-transformed cells
Jeffrey L. Platt, Chong Zhao, Jeffrey Chicca, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access | Times Cited: 1
Carfilzomib‐Induced Thrombotic Microangiopathy—Two Case Reports
Irene Attucci, Sofia Pilerci, Maria Messeri, et al.
Cancer Reports (2024) Vol. 7, Iss. 10
Open Access | Times Cited: 1
Proteasome inhibitors related thrombotic microangiopathy: a systematic and comprehensive review
Can Chen, Yiwei Li, Pengfei Shi, et al.
Blood Cancer Journal (2024) Vol. 14, Iss. 1
Open Access | Times Cited: 1
Kidney disease in multiple myeloma
Frank Bridoux, Nelson Leung, Samih H. Nasr, et al.
La Presse Médicale (2024), pp. 104264-104264
Closed Access | Times Cited: 1
Complement C3d enables cell-mediated immunity capable of distinguishing spontaneously transformed from nontransformed cells
Jeffrey L. Platt, Chong Zhao, Jeffrey Chicca, et al.
Proceedings of the National Academy of Sciences (2024) Vol. 121, Iss. 52
Open Access | Times Cited: 1
Delayed Onset of Thrombotic Microangiopathy (TMA) upon Prolonged Carfilzomib Therapy in Multiple Myeloma: A Case Report and Comprehensive Review
Andrea Ceglédi, Ágnes Király, Andrea Várkonyi, et al.
Pharmaceuticals (2024) Vol. 17, Iss. 12, pp. 1722-1722
Open Access | Times Cited: 1
Page 1

Scroll to top